What Anuh Pharma Ltd does

Anuh Pharma Limited is a publicly listed Indian Active Pharmaceutical Ingredient (API) manufacturer headquartered in Mumbai (Worli) and operating from the SK Group conglomerate. Founded in 1960 and BSE-listed since inception, the company gained an additional National Stock Exchange listing on 20 December 2024. It operates a 2,200 MTPA API manufacturing complex in Boisar, Tarapur (120 km from Mumbai) built to ICH-GMP standards, comprising six independent manufacturing blocks with 75+ KL of stainless-steel and glass-lined reactors and two airjet milling rooms, plus a DSIR-approved 10,000 sq ft R&D laboratory and pilot plant in Mahape, Navi Mumbai.

The company manufactures bulk drug substances across Macrolides (Erythromycin and salts, Azithromycin), Anti-TB (Pyrazinamide, Isoniazid), Anti-Malarial (Sulfadoxine, Pyrimethamine, Amodiaquine Hydrochloride), Anti-Bacterials, Anti-Hypertension (Losartan Potassium, Telmisartan), Anti-Diabetic (Gliclazide, Vildagliptin, Dapagliflozin), Expectorant (Ambroxol Hydrochloride), Anti-Gout and Cholesterol-lowering (Atorvastatin Calcium) categories. Corticosteroid APIs (Dexamethasone variants, Mometasone Furoate, Betamethasone Dipropionate, Prednisolone Sodium Phosphate, Clobetasol Propionate) are produced exclusively by Great Pacific Exports Pvt. Ltd. in Navi Mumbai under a loan-and-licence arrangement. Manufacturing is supported by analytical development for method validation, impurity profiling and stability studies.

Anuh generates revenue through direct B2B sales of APIs and corticosteroids to pharmaceutical formulators across 57+ countries, supplemented by supply into WHO-procured and donor-funded anti-malarial and TB programmes enabled by WHO-PQ certifications. Pricing is quote-based via a Get a Quote channel rather than publicly disclosed. Multi-regulatory approvals (USFDA EIR, EDQM CEPs for eight molecules, AEMPS-Spain EU-GMP, WHO-PQ for four molecules, CDSCO Written Confirmations, Mexican COFEPRIS) underpin eligibility for regulated global markets and are the principal basis of competitive differentiation. Marketing is concentrated in CPHI Worldwide, CPHI India and CPHI China trade shows alongside a recently strengthened investor relations programme following the NSE listing. The company is family-controlled, with Shah-family directors occupying senior executive and board positions, alongside independent directors with prior leadership experience at Zydus Cadila, Alembic, Bayer India, Cipla and Dr. Reddy's.

Name

Anuh Pharma Ltd

Legal name

Anuh Pharma Limited

Website

https://anuhpharma.com

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

251–500 employees

Short description

Anuh Pharma Limited is a publicly listed Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and corticosteroids, serving pharmaceutical formulators in 57+ countries through a 2,200 MTPA GMP-certified facility with USFDA, EU-GMP, EDQM CEP and WHO-PQ approvals.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Active pharmaceutical ingredients
• Macrolide antibiotics manufacturing
• Anti-tuberculosis APIs
• Anti-malarial APIs
• Corticosteroid manufacturing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: Manufacturing and sale of bulk drugs / Active Pharmaceutical Ingredients across therapeutic categories including Macrolides, Anti-TB, Anti-Malarial, Anti-Bacterials, Corticosteroids, Anti-Hypertension, Anti-Diabetic, Expectorant, and Anti-Gout. Revenue is generated through direct sales to pharmaceutical formulators globally.
2. Corticosteroid Manufacturing (Loan License): Corticosteroids manufactured exclusively at Great Pacific Exports Pvt. Ltd., Navi Mumbai under loan and licence arrangement. Revenue generated from sale of corticosteroids.
3. CEP and WHO-PQ Licensing: Revenue derived from CEP (Certificate of Suitability) and WHO-PQ (Prequalification) certifications enabling supply to international regulated markets and WHO/donor-funded public health procurement programmes.
4. WHO Public Health Procurement Supply: Supply of WHO-prequalified APIs (e.g., Amodiaquine Hydrochloride, Pyrazinamide, Sulfadoxine, Pyrimethamine) to WHO-procured and donor-funded anti-malarial programmes in malaria-endemic regions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Anuh Pharma manufactures and sells bulk Active Pharmaceutical Ingredients (APIs) across therapeutic categories including Macrolides (Erythromycin variants, Azithromycin), Anti-Tuberculosis (Pyrazinamide, Isoniazid), Anti-Malarial (Sulfadoxine, Pyrimethamine, Amodiaquine Hydrochloride), Corticosteroids (Dexamethasone, Mometasone, Betamethasone, Prednisolone, Clobetasol), and other categories such as Anti-Hypertension, Anti-Diabetic, and Expectorant APIs. Production is conducted at a 2,200 MTPA ICH-GMP compliant facility in Boisar, with corticosteroids manufactured under loan and licence at Great Pacific Exports Pvt. Ltd. in Navi Mumbai, supported by a DSIR-approved R&D laboratory for process development and scale-up.

Product overview

Anuh Pharma Ltd is a bulk drugs manufacturing company and part of the INR 8.5 billion SK Group. Established in 1960, it is one of the largest manufacturers of Macrolides and Anti-TB products in India, with a significant presence in Anti-Bacterials, Anti-Malarial, and Corticosteroids. The company offers two main product lines: Active Pharmaceutical Ingredients (APIs) including Macrolides (Erythromycin variants, Azithromycin), Anti-TB drugs (Pyrazinamide, Isoniazid), Anti-Malarial drugs (Sulfadoxine, Pyrimethamine, Amodiaquine Hydrochloride), and other therapeutic categories including Anti-Hypertension, Anti-Diabetic, Expectorant, Anti-Bacterial, and Anti-Gout medications. The second product line comprises Corticosteroids manufactured at Great Pacific Exports Pvt. Ltd. under loan and license arrangements. The company's manufacturing capacity stands at 2200 MTPA of APIs and intermediates, with facilities approved by EDQM, WHO-PQ, and holding Eu-GMP, USFDA, and Local-GMP certifications.

Differentiator

Problem solved

Functional benefit

Products and services

• Erythromycin Macrolide antibiotic API available in multiple grades including BP, EP, USP, and IP, with CEP and GMP certifications. CAS No. 114-07-8, C37H67NO13. Sold to pharmaceutical formulators as bulk API for finished oral solid antibiotic formulations.
• Erythromycin Ethyl Succinate Macrolide antibiotic salt form API with CEP, GMP, and Eu-GMP certifications. CAS No. 1264-62-6, C43H75NO16. Used by formulators for finished oral dosage forms.
• Erythromycin Stearate Macrolide antibiotic salt API with GMP certification. CAS No. 643-22-1, C55H103NO15.
• Erythromycin Estolate Macrolide antibiotic derivative API. CAS No. 3521-62-8, C52H97NO18S.
• Azithromycin Broad-spectrum macrolide antibiotic API with GMP and CEP certifications, supplied to global formulation customers.
• Pyrazinamide Anti-tubercular drug API with CEP, GMP, Eu-GMP, and WHO-PQ certifications. CAS No. 98-96-4, C5H5N3O. Used in fixed-dose combinations for TB treatment.
• Isoniazid Anti-tubercular drug API with GMP and WHO-PQ certifications. CAS No. 54-85-3, C6H7N3O. Used in first-line TB treatment regimens.
• Sulfadoxine Anti-malarial drug API with GMP and WHO-PQ certifications. CAS No. 2447-57-6, C12H14N4O4S. Used in combination with Pyrimethamine for malaria prophylaxis and treatment.
• Pyrimethamine Anti-malarial drug API with GMP and WHO-PQ certifications. CAS No. 58-14-0, C12H13ClN4. Used in anti-malarial fixed-dose combinations.
• Amodiaquine Hydrochloride Anti-malarial drug API used in treatment of uncomplicated Plasmodium falciparum malaria. CAS No. 69-44-3, C20H24Cl3N3O. WHO-PQ approved May 2026.
• Ambroxol Hydrochloride Expectorant API available in BP, EP, and IP grades with CEP certification. CAS No. 23828-92-4, C13H19Br2ClN2O.
• Gliclazide Anti-diabetic API (sulfonylurea) available in BP and EP grades with CEP certification. CAS No. 21189-98-4, C15H21N3O3S.
• Losartan Potassium Anti-hypertension drug API (Angiotensin Receptor Blocker). CAS No. 124750-99-8, C22H22ClKN6O.
• Dexamethasone Sodium Phosphate Corticosteroid API with anti-inflammatory and immunosuppressive properties. CAS No. 2392-39-4, C22H28FNa2O8P.
• Dexamethasone Acetate Corticosteroid API for anti-inflammatory applications. CAS No. 1177-87-3, C24H31FO6.
• Mometasone Furoate Topical corticosteroid API with anti-inflammatory properties. CAS No. 83919-23-7, C27H30Cl2O6.
• Betamethasone Dipropionate Corticosteroid API for inflammatory and pruritic conditions. CAS No. 5593-20-4, C28H37FO7.
• Prednisolone Sodium Phosphate Water-soluble corticosteroid API for anti-inflammatory use. CAS No. 125-02-0, C21H27Na2O8P.
• Clobetasol Propionate High-potency topical corticosteroid API with GMP and KFDA certifications. CAS No. 25122-46-7, C25H32ClFO5.

Quantifiable outcome

• WHO prequalification for Amodiaquine Hydrochloride API enables qualification as eligible supplier for WHO-procured anti-malarial programmes
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Great Pacific Exports Pvt. Ltd.coreOEM/ Whitelabel/ Licensing PartnerExclusive manufacturing partner for Corticosteroid products. Anuh Pharma's corticosteroids are manufactured exclusively at Great Pacific Exports Pvt. Ltd. in Navi Mumbai under a loan and licence arrangement. The facility is a state-of-the-art ICH-GMP compliant operation.
• World Health Organization (WHO)coreOthersWHO prequalified Anuh Pharma as an eligible supplier of Amodiaquine Hydrochloride USP (anti-malarial API) for WHO-procured and donor-funded anti-malarial programmes. This prequalification consolidates Anuh Pharma's position as a preferred API supplier for global public health procurement targeting malaria in sub-Saharan Africa and tropical regions.

Scale indicators9 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Divi's Laboratories: India's largest pure-play API and intermediates manufacturer with deep generic API expertise and strong USFDA/EDQM compliance. Closely comparable to Anuh as an API-focused Indian exporter competing in the same regulated generics market and serving global formulation customers.
• Granules India: Indian manufacturer of APIs, intermediates and finished formulations with USFDA-inspected facilities and a strong export orientation. Comparable to Anuh as a mid-cap Indian API exporter targeting regulated generics markets with vertically integrated formulation capabilities.
• Suven Pharmaceuticals: Indian CDMO and API manufacturer focused on niche molecules for global pharma customers. Comparable to Anuh in its API focus, B2B sales model and emphasis on USFDA/regulated-market compliance, though more concentrated in CDMO services.
• Hikal Limited: Indian manufacturer of APIs, intermediates and contract research services with strong pharma and crop-sciences businesses. Comparable to Anuh as a mid-cap Indian API and intermediates manufacturer with similar B2B export orientation and regulated-market focus.
• Ipca Laboratories: Indian manufacturer of APIs and formulations with strong anti-malarial, anti-infective and anti-arthritis franchises. Comparable to Anuh given overlapping therapeutic areas (anti-malarials, anti-infectives, anti-inflammatories) and similar global generics supply model.
• Neuland Laboratories: Indian API and contract manufacturing organisation serving global pharma with a portfolio focused on complex and niche APIs. Comparable to Anuh as a mid-sized Indian API manufacturer with USFDA-inspected facilities targeting regulated markets.
• IOL Chemicals and Pharmaceuticals: Indian manufacturer of APIs and bulk drugs including ibuprofen and other mature molecules with significant export share. Comparable to Anuh as a fellow Indian API manufacturer focused on off-patent molecules with multi-jurisdictional regulatory approvals.
• Laurus Labs: Indian API and CDMO player with strong anti-infectives and ARV franchise, supplying global generics and institutional buyers. Directly comparable to Anuh's positioning in Macrolide and anti-infective APIs with similar regulatory and export-driven business model.

Broad incumbents

• Alembic Pharmaceuticals: Long-established Indian manufacturer of APIs and finished formulations with a heritage of anti-infective manufacturing. Comparable to Anuh given overlapping Macrolide and anti-infective API history and a former Anuh board member served as Alembic executive for 25 years.
• Aurobindo Pharma: One of India's largest API and finished-formulation manufacturers with a broad anti-infectives portfolio and USFDA-inspected facilities. Comparable to Anuh as a fellow Indian API exporter serving global generics markets, though Aurobindo operates at substantially larger scale and across a wider therapeutic and finished-dose footprint.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/anuh-pharma-ltd

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anuh Pharma Ltd